药明生物与Bioasis建立战略合作
共同开发生产脑癌候选药物
WuXi Biologics and Bioasis Announce Initial Strategic Collaboration for the Development and Manufacturing of Bioasis’ Lead Investigational Candidate to Treat Brain Cancer
(*Please scroll down for English news.)
-Bioasis将借力药明生物丰富的生物药开发经验，推进xB³-001的工艺与制剂开发及临床试验申请进程
全球领先的生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）与加拿大生物技术公司Bioasis（TSX.V:BTI; OTCQB:BIOAF）今日宣布首次建立战略合作，共同开发及生产Bioasis公司用于治疗脑癌的生物候选药物xB³-001。
Bioasis是一家全球领先的生物制药公司，自主开发了独特的xB³专利技术平台，该平台能研发透过血脑屏障（BBB）的新疗法，有望治疗脑癌和神经退行性疾病等中枢神经系统疾病。
药明生物总部位于中国江苏无锡市，为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，其使命是加快和转变生物制药发现、开发及生产，造福全球患者。
大多数生物药目前无法用于治疗脑部疾病，面临的最大挑战是难以有效通过血脑屏障并递送入脑内，Bioasis开发设计的首款候选药物xB³-001有望解决这一难题。然而，生产此类复杂生物药需要在细胞株构建、工艺和制剂开发等方面具备强大的专业性和灵活性，通过定制化方案才能保证产品质量。
通过此次合作，Bioasis公司将借力药明生物在细胞株构建和开发、细胞培养工艺开发、纯化工艺开发以及制剂开发领域强大的技术和能力平台，助力Bioasis生产出制剂工艺上佳、稳定性优异及质量标准高的生物候选药物，用于临床试验开发。
“我们对公司领先项目xB³-001用于治疗HER2阳性乳腺癌脑转移患者的前景充满期待。”Bioasis总裁兼首席执行官Mark Day博士表示，“启动xB³-001的生产工作对Bioasis而言具有重大里程碑意义，相信药明生物的专业技术平台和丰富经验将有力推动Bioasis研发管线的开发进程。”
“我们非常高兴能够为合作伙伴Bioasis赋能，携手为广大脑癌患者开发创新疗法。”药明生物首席执行官陈智胜博士表示，此项合作能够充分发挥药明生物在生物制药领域的专业技术和经验，满足Bioasis从临床前开发、临床开发到上市阶段的一体化研发生产服务需求。
关于Bioasis
Bioasis是一家总部位于加拿大温哥华的生物制药上市公司，在美国康涅狄格州设有办事处。其在加拿大多伦多股票交易所（TSX）股票代码为BTI，在美国OTCQB代码为BIOAF。公司自主开发了独特的xB³专利技术平台，该平台能研发透过血脑屏障（BBB）的新疗法，用于治疗脑癌和神经退行性疾病等中枢神经系统疾病。如需更多信息，请访问：www.bioasis.ca或www.bioasis.us。
关于药明生物
药明生物作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。如需更多信息，请访问：www.wuxibiologics.com.cn。
WuXi Biologics and Bioasis Announce Initial Strategic Collaboration for the Development and Manufacturing of Bioasis’ Lead Investigational Candidate to Treat Brain Cancer
SHANGHAI China & VANCOUVER Canada,
May 21, 2018
- Bioasis will draw on WuXi Biologics’ expertise in developing complex biologic molecules for production of xB³-001 to support analytical development, formulation and IND-enabling in vivo studies
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), today announced an initial strategic collaboration for the development and manufacturing of xB³-001, Bioasis’ lead investigational biological candidate to treat brain cancer.
Bioasis is a biopharmaceutical company developing xB³, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, including brain cancers and neurodegenerative diseases.
Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.
The delivery of most biologics across the BBB and into the brain has been the single greatest challenge to treat brain diseases. Bioasis is engineering its first biologic product candidate, xB³-001, to overcome this obstacle in brain cancer. Manufacturing these sophisticated therapies requires a tailor-made approach, with expertise and agility in cell line, process and formulation development.
Through this partnership Bioasis will have access to WuXi Biologics’ extensive expertise and technologies from cell line construction and development, cell culture process development, purification process development and formulation development. WuXi Biologics will focus on ensuring that Bioasis’ drug product candidates are manufactured with optimal formulation, stability and exceptional quality for the clinic.
“The initiation of manufacturing for xB³-001 is a pivotal milestone for Bioasis as we look to advance our lead program in HER2+ breast cancer brain metastases,” said Dr. Mark Day, President and Chief Executive Officer, Bioasis. “WuXi Biologics’ expertise and experience in manufacturing biologics is instrumental to Bioasis in developing our pipeline.”
“We are excited to take on this work with Bioasis to enable them to bring innovative therapies to patients suffering from brain cancer,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. “This collaboration allows us to leverage our expertise across biological drug development and anticipate Bioasis’ needs as they move from pre-clinical to clinical and beyond.”
About Bioasis
Bioasis Technologies, Inc. is a biopharmaceutical company developing xB³, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Vancouver, Canada with offices in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF”. For more information about the company please visit www.bioasis.ca or www.bioasis.us.
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
注：本信息不构成药明生物的信息披露或投资建议
